|
| Status |
Public on Jul 25, 2019 |
| Title |
RNA-seq of breast cancer cell lines post ligand treatment II |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
Goal: study the impact of estrogen receptor ligands on gene expression in HR+ breast cancer cells
Methods: RNA sequencing
Results: Ligand 4-OH tamoxifen, a selective ER modulator (SERM), promotes transcriptional activation of ER and mimics the transcriptional effect of natural ligand E2 for a subset of ER target genes, consistently across the seven breast cell lines (MDA-MB-134 VI, MDA-MB-330, EFM-19, T-47D, and BT-474). Selective ER degraders (SERD) fulvestrant and GDC-0927 on the other hand do not induce, or induce very weakly the expression of ER target genes. The effect of GDC-0810 depends on the cellular context.
|
| |
|
| Overall design |
Duplicates results of RNA-Seq of seven cell lines treated with six different estrogen receptor ligands or DMSO for 24 hours
|
| |
|
| Contributor(s) |
Metcalfe C, Daemen A, Hafner M, Zhou W |
| Citation(s) |
31353221 |
| |
| Submission date |
Mar 27, 2019 |
| Last update date |
Oct 29, 2019 |
| Contact name |
Marc Hafner |
| E-mail(s) |
hafner.marc@gene.com
|
| Organization name |
Genentech
|
| Department |
Oncology Bioinformatics
|
| Street address |
Building 45-1, 1 DNA Way
|
| City |
South San Francisco |
| State/province |
CA |
| ZIP/Postal code |
94080 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL20301 |
Illumina HiSeq 4000 (Homo sapiens) |
|
| Samples (38)
|
|
| This SubSeries is part of SuperSeries: |
| GSE117943 |
ATAC-seq, ChIP-seq and RNA-seq of breast cancer cell lines post ligand treatment |
|
| Relations |
| BioProject |
PRJNA529360 |
| SRA |
SRP189565 |
Less...
More...